Loading...
Market
What will be Judo Bio's major clinical milestone by end of 2026?
2
Resolution / Starting Odds
Preclinical success • 25%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 initiation • 25%
Company announcements or clinical trial registry updates
Story
Judo Bio Launches with $100M to Develop RNA Kidney Drugs Using STRIKE Platform
Oct 7, 2024, 12:16 PM
Judo Bio has debuted with a $100 million launch, aiming to develop RNA drugs targeting the kidney. The company plans to utilize its Selectively Targeting RNA Into KidnEy (STRIKE) platform to develop ligand-siRNA conjugates. The launch comes less than two months after Borealis Bio's $150 million launch for similar RNA kidney drugs. Judo Bio's leadership includes CEO Rajiv Patni and CSO Alfica Sehgal, with backing from Atlas Venture and TCG. The company is taking a page from Alnylam's playbook and is part of the broader startups ecosystem.
View original story
Similar markets
FDA approval of JNT-517 • 25%
Initiation of Phase 3 trials for JNT-517 • 25%
New drug discovery announcement • 25%
Other • 25%
Dose escalation • 25%
Safety assessment • 25%
Efficacy assessment • 25%
Trial termination • 25%
Phase II trial results • 25%
Phase III trial initiation • 25%
New partnership announcement • 25%
Other • 25%
Proof-of-concept data achieved • 25%
Partnership announcement • 25%
Regulatory approval submission • 25%
No major milestone achieved • 25%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 completion • 25%
No significant milestone • 25%
Phase II trial completion • 25%
Phase III trial commencement • 25%
FDA approval • 25%
None of the above • 25%
Phase 2 trial completion • 25%
Phase 3 trial initiation • 25%
Regulatory approval in any region • 25%
No significant milestone • 25%
Phase 2 completion • 25%
Phase 3 initiation • 25%
Regulatory approval submission • 25%
No significant milestone • 25%
Successful Phase I trial • 25%
FDA Fast Track designation • 25%
Publication of promising preclinical results • 25%
No major milestone achieved • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
FDA Approval • 25%
EMA Approval • 25%
Additional Phase 3 Trials • 25%
Other • 25%
Improved survival rates • 25%
Increased cancer rates • 25%
Stable condition • 25%
Other • 25%